Gone from the American Society of Clinical Oncology (ASCO) meeting were the packed halls of McCormick Place in Chicago and the excited bustle of scientists reacquainting with each other at the always data-rich event. ASCO’s annual confab, held online because of the COVID-19 pandemic, still managed to pull off what former president Howard Burris called a “resounding success,” with about 40,000 registrants, similar to previous years.
Blue chip public biopharmaceutical companies continued their positive trajectory in May, with the BioWorld Biopharmaceutical index recording an 8% jump in valuation and contributing to its year-to-date performance of approximately 17%.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: 3nt Medical, Abiomed, Healgen Scientific, Meditech Spine, Rhaeos, Siemens Healthineers, Tissue Regenix.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Allergan Aesthetics, Atron Group Avista Capital Partners, Celonova Biosciences, Clarion Medical Technologies, Designplex Biomedical, Evo Design, Ibuttonlink, Ideal Medical, Jet Propulsion Laboratory, Labcorp, Mvent, Minnetronix, Nanovibronix, Pro-Dex, Quanta, Richards Packaging Income Fund, Stark Industries, University of New Mexico, Vacumed, Vacumetrics, Vision Healthcare, Visionquest.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbvie, Accord, Altimmune, ANI, Astrazeneca, Aveo, Compugen, Cytodyn, Eli Lilly, Genentech, Henlius, Hutchison China (Chi-Med), J&J, Longeveron, Merck, Mundipharma, Myovant, Myr, Opko.